Vaxcyte announced that it has commenced an underwritten public offering of $1.0B of its common stock and pre-funded warrants. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. BofA Securities, Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities and Mizuho are acting as joint book-running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX:
- Vaxcyte price target raised to $153 at Leerink after VAX-31 ‘home run’
- Needham ups Vaxcyte target to $140 after ‘best-case scenario’ data
- Vaxcyte price target raised to $140 from $95 at Needham
- ESPN goes dark on DirecTV, Harris to oppose Nippon-U.S. Steel deal: Morning Buzz
- Vaxcyte price target raised to $160 from $98 at BTIG